#EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes

Data ReadoutpositiveeloraTZPZepboundPositive

AI Analysis

Summary

Eli Lilly announced positive data for eloraTZP, an amylin-incretin combination treatment, showing weight loss of up to 23.3% in patients with obesity and diabetes at EASD26 conference.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

weight loss of up to 23.3% with amylin-incretin combination

Importance:7/10

Sentiment:

0.85

obesitydiabetesweight lossGLP-1amylinEASD26clinical data

Related Companies

$LLY

Read the original article

Published by Endpoints News on September 30, 2026 2:15 PM

Read Original